about
Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonistsGlutamatergic targets for new alcohol medicationsPreclinical evaluation of the antipsychotic potential of the mGlu2-positive allosteric modulator JNJ-40411813.Neuronal mechanisms underlying development of nicotine dependence: implications for novel smoking-cessation treatments.Group II metabotropic glutamate receptor agonist LY379268 regulates AMPA receptor trafficking in prefrontal cortical neurons.Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: stress and depression.Metabotropic Glutamate Receptors: MODULATORS OF CONTEXT-DEPENDENT FEEDING BEHAVIOUR IN C. ELEGANSGenetic, pharmacological and lesion analyses reveal a selective role for corticohippocampal GLUN2B in a novel repeated swim stress paradigm.Selective silencing of individual dendritic branches by an mGlu2-activated potassium conductance in dentate gyrus granule cellsPractical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate ReceptorsIn the grey zone between epilepsy and schizophrenia: alterations in group II metabotropic glutamate receptors.Indanes--Properties, Preparation, and Presence in Ligands for G Protein Coupled Receptors.Reduction in Migratory Phenotype in a Metastasized Breast Cancer Cell Line via Downregulation of S100A4 and GRM3.Advances in the genetics of schizophrenia: toward a network and pathway view for drug discovery.Metabotropic Glutamate Receptors 2 and 3 as Targets for Treating Nicotine Addiction.
P2860
Q22251267-FADF4A61-30F7-43D2-AF54-DA035D59B09CQ26824012-9F2B493D-104D-464B-8DBB-133EA9ECBFCAQ30418647-A91894D9-8898-4666-8091-6B765CD1E9D2Q34224871-6D24B50F-74C6-4937-A4AF-85B7DE0945E3Q34675038-FADA213B-F557-476D-B31C-2E4837C33955Q35237104-6F6396E9-2B6B-4C1A-910D-352C77D029E9Q35721772-3BA947E7-C21E-4066-B7AC-32D66D1A5FE0Q36700393-5E4C29A7-7FB4-4B8D-ACB6-42909BF182BFQ36810516-94C60846-79AD-4C32-A1F0-2D3DC86CE2C8Q37183072-717A2312-0C50-4057-A718-34F2D87C527DQ38300355-16ABD050-41C7-4B16-8A01-0A020F511936Q38505134-47111AE7-37F9-44E7-A0E9-8B990C71E0C3Q38700311-501B6397-AE91-4320-998D-368B4F29F04AQ38816605-1D9DC8F8-B3D9-40D7-989D-0F6705DCEFD3Q47663907-E9EB7AE8-1904-49D0-A4F2-C3B05D1B80A5
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Promise of mGluR2/3 activators in psychiatry
@ast
Promise of mGluR2/3 activators in psychiatry
@en
Promise of mGluR2/3 activators in psychiatry
@nl
type
label
Promise of mGluR2/3 activators in psychiatry
@ast
Promise of mGluR2/3 activators in psychiatry
@en
Promise of mGluR2/3 activators in psychiatry
@nl
prefLabel
Promise of mGluR2/3 activators in psychiatry
@ast
Promise of mGluR2/3 activators in psychiatry
@en
Promise of mGluR2/3 activators in psychiatry
@nl
P2860
P356
P1476
Promise of mGluR2/3 activators in psychiatry
@en
P2093
Carrie K Jones
P2860
P2888
P356
10.1038/NPP.2008.156
P407
P577
2009-01-01T00:00:00Z
P5875
P6179
1009458907